Research Grade Tixagevimab (AZD8895) (DVV00308);Research Grade Tixagevimab
用途
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the receptor-binding domain (RBD) of SARS-CoV-2; it exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S glycoprotein ectodomain, thereby blocking S glycoprotein-mediated binding to its receptor.